MedDataX Logo

Bacille Calmette-Guérin (BCG) Vaccine and Atopy

NCT ID: NCT01420705

Last Updated: 2011-12-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

487 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-10-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The prevalence of asthma and allergic diseases is increasing worldwide. Infections and vaccinations in childhood may have an impact on the subsequent development of asthma and allergy. In Guinea-Bissau, the investigators previously found that Bacille Calmette-Guérin (BCG) vaccine was associated with reduction in atopy. Since then the investigators have conducted a randomised trial of BCG vaccine given at birth to low birth-weight infants. The present study aims to follow up children enrolled in the BCG randomised trial to assess for asthma and allergy later in childhood. Based on previous observations, the investigators expect children allocated to receive BCG at birth will have a reduction in allergy profile when compared to children who did not receive BCG at birth.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Prevalence of asthma and allergy is increasing worldwide, and the cause is unclear. Previous work by the Bandim Health Project and others has identified that infections and routine childhood vaccinations have an impact on the development of atopic sensitisation and allergic symptoms later in life. A number of these studies have found association between BCG vaccination and reduction in atopy and allergy. Only one randomised trial has been conducted of BCG vaccine to protect against allergy with inconclusive results. The present project provides the opportunity to follow-up children born low birth-weight who were randomised to receive BCG vaccine at birth or to receive BCG later in infancy as part of regular care.

Hypothesis:

* Children given BCG vaccine at birth will have reduced prevalence of positive skin-prick test and allergic symptoms when compared with children who did not receive BCG at birth
* Early BCG vaccination will be associated with reduced prevalence of positive skin prick test and allergic symptoms
* Early DTP vaccination will be associated with increased prevalence of positive skin-prick tests and allergic symptoms

Objectives:

* to examine the effects of environmental factors, including BCG, DTP and measles vaccines, on atopy (determined by skin-prick tests) and symptoms of asthma, eczema and food allergy
* to examine the sex-differential effects of vaccination on atopy and allergic symptoms
* to determine the association between faecal microbial diversity, atopy and food allergy

Methods: children previously enrolled in NCT00146302 will followed up at home (currently aged 3-9 years) and tested for atopic sensitisation with skin-prick tests and presence of allergic symptoms determined by questionnaire.

Sample size: 812 children from the Bandim Health Project study area were enrolled in the randomised trial. The investigators anticipate to be able to follow up approximately 487 of these children, which will have the power to detect a 30% difference in atopic sensitisation between groups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Eczema Food Hypersensitivity

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Bacille Calmette-Guérin DTP Vaccination Allergy Atopy Guinea-Bissau

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low birth-weight cohort

Children previously enrolled in randomised trial NCT00146302 who are currently living within the Bandim Health Project study area

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Previous enrolment in NCT00146302
* Living within Bandim Health Project study area

Exclusion Criteria

* Children with known history of anaphylaxis
* Children with skin infections or severe skin conditions for who SPT could not be reliably performed
* Children currently taking anti-histamine medication
Minimum Eligible Age

3 Years

Maximum Eligible Age

9 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Murdoch Childrens Research Institute

OTHER

Sponsor Role collaborator

Bandim Health Project

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bandim Health Project

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Aaby, DMSc

Role: PRINCIPAL_INVESTIGATOR

Bandim Health Project

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bandim Health Project

Bandim, , Guinea-Bissau

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Guinea-Bissau

References

Explore related publications, articles, or registry entries linked to this study.

Kiraly N, Benn CS, Biering-Sorensen S, Rodrigues A, Jensen KJ, Ravn H, Allen KJ, Aaby P. Vitamin A supplementation and BCG vaccination at birth may affect atopy in childhood: long-term follow-up of a randomized controlled trial. Allergy. 2013 Sep;68(9):1168-76. doi: 10.1111/all.12216. Epub 2013 Aug 31.

Reference Type DERIVED
PMID: 23991838 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.bandim.org

Related Info

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2011-BHP-LBW-BCG-atopy

Identifier Type: -

Identifier Source: org_study_id